文献速递脑血管病

限制性取栓试验入选标准的问题

The Problem of Restrictive Thrombectomy Trial Eligibility Criteria.
PubMed 文献 · Stroke · 2022-07-25

自2015年以来,一系列血管内试验改变了大型血管闭塞性卒中的管理。多数取栓试验采用限制性入选标准以优化显示取栓有效的机会,但将试验结果推广为循证推荐时出现问题。许多机构将限制性试验入选标准逐字转化为权威指南,限制取栓仅用于高度选择患者。本文评论提出分层方法,以更严格检验和确认治疗获益人群边界。

要点

  • 多数取栓试验采用限制性入选标准,将结果推广为指南时需谨慎。
  • 许多机构将限制性试验标准逐字转化为指南,限制取栓使用。
  • 作者提出分层方法以更严格检验治疗获益人群边界。

核心结论

  • 取栓试验应纳入所有可能获益的患者,而非仅限高度选择人群。
  • 作者提出分层方法,以更严格检验和确认治疗获益人群边界。
  • 在制定指南前识别可能获益患者,可避免忽视这些个体。

研究设计与样本

  • 本文为评论文章,讨论限制性取栓试验入选标准的问题及推广至指南的挑战。

主要发现

  • 多数取栓试验使用限制性入选标准以优化显示取栓有效的机会。
  • 许多组织将限制性试验入选标准逐字转化为权威指南,限制取栓仅用于高度选择患者。
  • 限制性试验标准、相应限制性指南、观察性研究显示其他患者获益、需新试验的循环反复出现。
  • D. Sackett提出解决方案:使用相同标准,预先指定最可能获益的亚组,而非选择部分患者排除其他。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since 2015, a series of endovascular trials transformed the management of patients with large vessel occlusion stroke. Most thrombectomy trials used restrictive eligibility criteria to optimize the chances of showing that thrombectomy could work. The problem arises when generalizing trial results into evidence-based recommendations. Many organizations, oblivious of this problem, translated verbatim restrictive trial eligibility criteria into authoritative guidelines, which limit the use of thrombectomy to highly selected patients. The clinical problem becomes as follows: what to do for all other stroke patients equally in need of care? The cycle of restrictive trial eligibility criteria, corresponding restrictive guidelines, observational studies of unvalidated practices showing other patients benefit, a new trial is needed, has been repeated often. Thrombectomy trials ought to have included all patients that could potentially benefit. If the signal that was looked for by restricting eligibility is at risk of being lost in the noise generated by the heterogeneity of patients, D. Sackett proposed a solution: to use the same criteria, not to select some patients and exclude others but to prespecify the subgroup of patients most likely to benefit. In this commentary, we propose a tiered approach, where the boundaries of treatment beneficiaries can be more rigorously tested and confirmed. Identification of these patients before the development of guidelines, which would have otherwise neglected these individuals, may open innumerable treatment opportunities to those who will instead be denied of them.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Nguyen TN, Raymond J, Nogueira RG, et al. The Problem of Restrictive Thrombectomy Trial Eligibility Criteria. Stroke. 2022. PMID: 35876017. doi:10.1161/STROKEAHA.122.040006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。